Table 6.

Sensitivity of multivariate risk stratification from CA125, ROMA and MIA2G by stage and grade of primary ovarian malignancy—all evaluable subjects

	CA125	ROMA	MIA2G
Stage I, %	55.9	67.8	86.4
n/N	33/59	40/59	51/59
95% CI	43.3–67.8	55.1–78.3	75.5–93.0
Stage II, %	80.0	96.0	100.0
n/N	20/25	24/25	25/25
95% CI	60.9–91.1	80.5–99.3	86.7–100.0
Stage III, %	97.2	97.2	100.0
n/N	70/72	70/72	72/72
95% CI	90.4–99.2	90.4–99.2	94.9–100.0
Stage IV, %	100.0	100.0	100.0
n/N	8/8	8/8	8/8
95% CI	67.6–100.0	67.6–100.0	67.6–100.0
Not staged, %	0.0	50.0	50.0
n/N	0/2	1/2	1/2
95% CI	0.0–65.8	9.5–90.5	9.5–90.5
Early stage (I and II), %	63.1	76.2	90.5
n/N	53/84	64/84	76/84
95% CI	52.4–72.6	66.1–84.0	82.3–95.1
Late stage (III and IV), %	97.5	97.5	100.0
n/N	78/80	78/80	80/80
95% CI	91.3–99.3	91.3–99.3	95.4–100.0
All primary, %	78.9	86.1	94.6
n/N	131/166	143/166	157/166
95% CI	72.1–84.4	80.1–90.6	90.0–97.1
Grade 3 serous, %	96.7	98.4	100.0
n/N	59/61	60/61	61/61
95% CI	88.8–99.1	91.3–99.7	94.1–100.0
Other grade 3, %	87.2	87.2	97.4
n/N	34/39	34/39	38/39
95% CI	73.3–94.4	73.3–94.4	86.8–99.5
Grade 2, %	68.6	82.9	91.4
n/N	24/35	29/35	32/35
95% CI	52.0–81.4	67.3–91.9	77.6–97.0
Grade 1, %	45.0	70.0	90.0
n/N	9/20	14/20	18/20
95% CI	25.8–65.8	48.1–85.5	69.9–97.2
Not graded, %	45.5	54.5	72.7
n/N	5/11	6/11	8/11
95% CI	21.3–72.0	28.0–78.7	43.4–90.3

CA125 high-risk cutoff: premenopausal subjects > 200 U/ml; postmenopausal subjects > 35 U/ml

ROMA high-risk cutoff: premenopausal subjects ≥ 11.4; postmenopausal subjects ≥ 29.9